Michael Burkes Brophy Sells 1,867 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,867 shares of Natera stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $230.40, for a total transaction of $430,156.80. Following the completion of the transaction, the chief financial officer directly owned 59,059 shares in the company, valued at $13,607,193.60. This represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The stock was sold at an average price of $237.56, for a total value of $573,232.28.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total value of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Stock Performance

NTRA stock traded down $4.45 during trading on Thursday, reaching $231.48. The company had a trading volume of 947,123 shares, compared to its average volume of 1,043,018. The company has a market cap of $32.02 billion, a price-to-earnings ratio of -101.08 and a beta of 1.62. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36. The firm has a 50-day simple moving average of $235.90 and a 200-day simple moving average of $193.29.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Citigroup started coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective for the company. Piper Sandler boosted their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. UBS Group increased their price target on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Barclays boosted their price objective on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Stephens upped their target price on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.20.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Flagship Harbor Advisors LLC acquired a new stake in Natera during the 4th quarter worth $41,000. Hilltop National Bank purchased a new stake in Natera during the 2nd quarter valued at about $33,000. Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter valued at about $32,000. Sound Income Strategies LLC raised its holdings in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new position in Natera in the 4th quarter worth approximately $62,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
• Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.